Vegzelma (bevacizumab)

pCPA File Number: 21952

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma

Sponsor/Manufacturer:

Celltrion Healthcare Canada Ltd.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2023-01-10

Negotiation Process Concluded:

2023-03-23